Söndag 22 December | 04:06:50 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2025-11-12 07:30 Kvartalsrapport 2025-Q3
2025-08-20 07:30 Kvartalsrapport 2025-Q2
2025-05-14 07:30 Kvartalsrapport 2025-Q1
2025-03-26 N/A Årsstämma
2025-02-05 07:30 Bokslutskommuniké 2024
2024-11-13 - Kvartalsrapport 2024-Q3
2024-08-21 - Kvartalsrapport 2024-Q2
2024-05-15 - Kvartalsrapport 2024-Q1
2024-03-21 - X-dag ordinarie utdelning HLUN B 0.70 DKK
2024-03-21 - X-dag ordinarie utdelning HLUN A 0.70 DKK
2024-03-20 - Årsstämma
2024-02-07 - Bokslutskommuniké 2023
2023-11-08 - Kvartalsrapport 2023-Q3
2023-08-16 - Kvartalsrapport 2023-Q2
2023-05-10 - Kvartalsrapport 2023-Q1
2023-03-22 - X-dag ordinarie utdelning HLUN B 0.58 DKK
2023-03-22 - X-dag ordinarie utdelning HLUN A 0.58 DKK
2023-03-22 - X-dag bonusutdelning HLUN A 0.58
2023-03-21 - Årsstämma
2023-02-08 - Bokslutskommuniké 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-08-17 - Kvartalsrapport 2022-Q2
2022-06-10 - Split HLUN B 1:5
2022-06-08 - Extra Bolagsstämma 2022
2022-05-11 - Kvartalsrapport 2022-Q1
2022-03-24 - X-dag ordinarie utdelning HLUN B 2.00 DKK
2022-03-23 - Årsstämma
2022-02-09 - Bokslutskommuniké 2021
2021-11-10 - Kvartalsrapport 2021-Q3
2021-08-18 - Kvartalsrapport 2021-Q2
2021-05-11 - Kvartalsrapport 2021-Q1
2021-03-24 - X-dag ordinarie utdelning HLUN B 2.50 DKK
2021-03-23 - Årsstämma
2021-02-04 - Bokslutskommuniké 2020
2020-11-03 - Kvartalsrapport 2020-Q3
2020-08-13 - Kvartalsrapport 2020-Q2
2020-05-12 - Kvartalsrapport 2020-Q1
2020-03-25 - X-dag ordinarie utdelning HLUN B 4.10 DKK
2020-03-24 - Årsstämma
2020-02-06 - Bokslutskommuniké 2019
2019-11-05 - Kvartalsrapport 2019-Q3
2019-08-14 - Kvartalsrapport 2019-Q2
2019-05-08 - Kvartalsrapport 2019-Q1
2019-03-27 - X-dag ordinarie utdelning HLUN B 12.00 DKK
2019-03-26 - Årsstämma
2019-02-05 - Bokslutskommuniké 2018
2018-11-07 - Kvartalsrapport 2018-Q3
2018-08-08 - Kvartalsrapport 2018-Q2
2018-05-08 - Kvartalsrapport 2018-Q1
2018-03-21 - X-dag ordinarie utdelning HLUN B 8.00 DKK
2018-03-20 - Årsstämma
2018-02-07 - Bokslutskommuniké 2017
2017-11-08 - Kvartalsrapport 2017-Q3
2017-08-09 - Kvartalsrapport 2017-Q2
2017-05-10 - Kvartalsrapport 2017-Q1
2017-03-31 - X-dag ordinarie utdelning HLUN B 2.45 DKK
2017-03-30 - Årsstämma
2017-02-08 - Bokslutskommuniké 2016
2016-11-02 - Kvartalsrapport 2016-Q3
2016-08-24 - Kvartalsrapport 2016-Q2
2016-05-11 - Kvartalsrapport 2016-Q1
2016-04-01 - X-dag ordinarie utdelning HLUN B 0.00 DKK
2016-03-31 - Årsstämma
2016-02-10 - Bokslutskommuniké 2015
2015-11-04 - Kvartalsrapport 2015-Q3
2015-08-19 - Kvartalsrapport 2015-Q2
2015-05-06 - Kvartalsrapport 2015-Q1
2015-03-26 - X-dag ordinarie utdelning HLUN B 0.00 DKK
2015-03-25 - Årsstämma
2015-02-05 - Bokslutskommuniké 2014
2014-11-05 - Kvartalsrapport 2014-Q3
2014-08-07 - Kvartalsrapport 2014-Q2
2014-05-07 - Kvartalsrapport 2014-Q1
2014-03-27 - X-dag ordinarie utdelning HLUN B 2.77 DKK
2014-03-26 - Årsstämma
2014-02-06 - Bokslutskommuniké 2013
2013-11-06 - Kvartalsrapport 2013-Q3
2013-08-07 - Kvartalsrapport 2013-Q2
2013-05-01 - Kvartalsrapport 2013-Q1
2013-03-22 - X-dag ordinarie utdelning HLUN B 2.00 DKK
2013-03-21 - Årsstämma
2013-02-06 - Bokslutskommuniké 2012
2012-11-07 - Kvartalsrapport 2012-Q3
2012-08-08 - Kvartalsrapport 2012-Q2
2012-05-02 - Kvartalsrapport 2012-Q1
2012-03-30 - X-dag ordinarie utdelning HLUN B 3.49 DKK
2012-03-29 - Årsstämma
2012-02-08 - Bokslutskommuniké 2011
2011-11-09 - Kvartalsrapport 2011-Q3
2011-08-10 - Kvartalsrapport 2011-Q2
2011-05-04 - Kvartalsrapport 2011-Q1
2011-03-31 - X-dag ordinarie utdelning HLUN B 3.77 DKK
2011-03-30 - Årsstämma
2010-04-21 - X-dag ordinarie utdelning HLUN B 3.07 DKK
2009-04-22 - X-dag ordinarie utdelning HLUN B 2.30 DKK

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriLäkemedel & Handel
Lundbeck är ett läkemedelsbolag. Störst fokus återfinns inom forskning om psykiatriska och neurotiska störningar, vilket innefattar behandling av depression, schizofreni, Alzheimers och Parkinsons syndrom. Bolaget bedriver forskning, utveckling och distribution av läkemedel där kundbasen återfinns på global nivå. Bolaget grundades ursprungligen under 1915 och har sitt huvudkontor i Valby.
2024-02-05 15:00:00

H. Lundbeck A/S (Lundbeck) today announced the appointment of Dianne Hol to the role of EVP, People & Organization. Dianne will join Lundbeck on 1 April 2024 and will be part of the Executive Management.

Dianne will be responsible for driving Lundbeck's people strategy to support its growth journey and assist in developing the organization further. With an impressive international background in HR leadership, Dianne brings a wealth of experience and expertise to Lundbeck.  Her track record speaks volumes about her capability to enhance both company and people's performance, while also building high-performing HR teams.

"I look forward to welcoming Dianne to her new position in Lundbeck, says Charl van Zyl; President and CEO of Lundbeck. With her proven track record of driving performance and fostering talent, I'm confident that her leadership will play a crucial role in propelling our company forward."

"I'm excited to be a part of Lundbeck's mission to improve the lives of people living with brain disorders through a clear people strategy which fosters a culture of innovation and where every person can thrive and perform at their best," says Dianne Hol.

Dianne joins Lundbeck from AstraZeneca where she served as Vice President Global Human Resources in different global business areas, latest in BioPharmaceuticals & Japan. Prior to this, she was Global Head of Human Resources Roche Diabetes Care. Dianne is Dutch and holds a Bachelor of Arts Human Resources Management Hogeschool van Utrecht, Netherlands.

Contacts

Thomas Mikkel Mortensen Palle Holm Olesen
Media Relations Lead, Corp. Communication Vice President, Investor Relations
THMR@lundbeck.com PALO@lundbeck.com
+45 30 83 30 24 +45 30 83 24 26

Sophia Nørskov Bech
Senior Manager, Investor Relations
SONQ@lundbeck.com
+45 30 83 24 60

About H. Lundbeck A/S
Lundbeck is a biopharmaceutical company focused exclusively on neuroscience, with more than 70 years of experience in improving the lives of people with neurological and psychiatric diseases.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex challenges. We develop transformative medicines targeting people for whom there are few, if any, treatment options.

Our goal is to create long term value and make a positive contribution to people and societies, everywhere we operate. We are committed to fighting stigma and discrimination, and we act to improve health equity for the people we serve and the communities we are part of. 

For additional information, we encourage you to visit our corporate site www.lundbeck.com (https://www.lundbeck.com/global) and connect with us via LinkedIn (https://www.linkedin.com/company/lundbeck/).